NASDAQ:SRNE - Sorrento Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.28 -0.05 (-1.50 %) (As of 11/20/2018 11:31 AM ET)Previous Close$3.33Today's Range$3.18 - $3.3952-Week Range$2.15 - $10.65Volume21,460 shsAverage Volume1.73 million shsMarket Capitalization$453.64 millionP/E Ratio25.31Dividend YieldN/ABeta2.48 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California. Receive SRNE News and Ratings via Email Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRNE Previous Symbol CUSIPN/A Webwww.sorrentotherapeutics.com Phone858-203-4100 Debt Debt-to-Equity Ratio0.65 Current Ratio1.76 Quick Ratio1.76 Price-To-Earnings Trailing P/E Ratio25.31 Forward P/E Ratio-2.02 P/E GrowthN/A Sales & Book Value Annual Sales$151.86 million Price / Sales2.64 Cash Flow$0.1784 per share Price / Cash18.39 Book Value$2.50 per share Price / Book1.31 Profitability EPS (Most Recent Fiscal Year)$0.13 Net Income$9.13 million Net Margins-303.79% Return on Equity-46.62% Return on Assets-22.72% Miscellaneous Employees162 Outstanding Shares122,270,000Market Cap$453.64 million OptionableOptionable Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions What is Sorrento Therapeutics' stock symbol? Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE." When is Sorrento Therapeutics' next earnings date? Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 22nd 2018. View Earnings Estimates for Sorrento Therapeutics. What price target have analysts set for SRNE? 3 equities research analysts have issued 1-year price targets for Sorrento Therapeutics' shares. Their predictions range from $10.00 to $40.00. On average, they expect Sorrento Therapeutics' share price to reach $21.4167 in the next twelve months. This suggests a possible upside of 552.9% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics. What is the consensus analysts' recommendation for Sorrento Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics. Has Sorrento Therapeutics been receiving favorable news coverage? Press coverage about SRNE stock has been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sorrento Therapeutics earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Sorrento Therapeutics' key competitors? Some companies that are related to Sorrento Therapeutics include Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), HedgePath Pharmaceuticals (HPPI), Dyadic International (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), US Stem Cell (USRM), Protalex (PRTX), Tenax Therapeutics (TENX), Geovax Labs (GOVX) and ALGAE TEC LTD/S (ALGXY). Who are Sorrento Therapeutics' key executives? Sorrento Therapeutics' management team includes the folowing people: Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 54)Mr. George K. Ng, Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 68)Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 50)Dr. Alexis Nahama, VP of Corp. Devel. Who are Sorrento Therapeutics' major shareholders? Sorrento Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.40%), Bank of New York Mellon Corp (0.34%), FMR LLC (0.31%), Vident Investment Advisory LLC (0.27%), AXA (0.25%) and AQR Capital Management LLC (0.23%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Pacific Medtech (Bvi) Ltd Asia and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics. Which institutional investors are selling Sorrento Therapeutics stock? SRNE stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Renaissance Technologies LLC, Virtus ETF Advisers LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., First Republic Investment Management Inc. and Vident Investment Advisory LLC. Company insiders that have sold Sorrento Therapeutics company stock in the last year include Abg Management Ltd and Pacific Medtech (Bvi) Ltd Asia. View Insider Buying and Selling for Sorrento Therapeutics. Which institutional investors are buying Sorrento Therapeutics stock? SRNE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Man Group plc, AXA, Russell Investments Group Ltd., AQR Capital Management LLC, Bank of New York Mellon Corp and TCW Group Inc.. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics. How do I buy shares of Sorrento Therapeutics? Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sorrento Therapeutics' stock price today? One share of SRNE stock can currently be purchased for approximately $3.28. How big of a company is Sorrento Therapeutics? Sorrento Therapeutics has a market capitalization of $453.64 million and generates $151.86 million in revenue each year. The biopharmaceutical company earns $9.13 million in net income (profit) each year or $0.13 on an earnings per share basis. Sorrento Therapeutics employs 162 workers across the globe. What is Sorrento Therapeutics' official website? The official website for Sorrento Therapeutics is http://www.sorrentotherapeutics.com. How can I contact Sorrento Therapeutics? Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected] MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 393 (Vote Outperform)Underperform Votes: 187 (Vote Underperform)Total Votes: 580MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: What is the float in trading stocks?